Zeo ScientifiX, Inc. financial data

Symbol
OCEL on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
3321 College Avenue, Suite 246, Davie, Florida
State of incorporation
Nevada
Fiscal year end
October 31
Former names
Organicell Regenerative Medicine, Inc. (to 1/29/2024), Biotech Products Services & Research, Inc. (to 6/15/2018), BESPOKE TRICYCLES INC (to 9/14/2015)
Latest financial report
Q1 2024 - Jun 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 44.3 % -15%
Quick Ratio 7.77 % +57%
Debt-to-equity -276 % +67.6%
Return On Assets -214 % +12.2%
Operating Margin -110 % +44.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.33 M shares -99.6%
Common Stock, Shares, Outstanding 6.33 M shares -99.6%
Entity Public Float 7.2 M USD -39.8%
Common Stock, Value, Issued 6 K USD -99.6%
Weighted Average Number of Shares Outstanding, Basic 6.17 M shares -15%
Weighted Average Number of Shares Outstanding, Diluted 6.17 M shares -15%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 4.93 M USD -2.83%
Cost of Revenue 739 K USD +7.05%
Research and Development Expense 354 K USD -57.9%
General and Administrative Expense 9.59 M USD -33.4%
Operating Income (Loss) -5.4 M USD +46.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -9.49 M USD -50.6%
Net Income (Loss) Attributable to Parent -5.15 M USD +48.7%
Earnings Per Share, Basic -0.79 USD/shares +14.8%
Earnings Per Share, Diluted -0.79 USD/shares +14.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.42 M USD +846%
Accounts Receivable, after Allowance for Credit Loss, Current 60 K USD +362%
Inventory, Net 272 K USD +7.71%
Assets, Current 1.42 M USD -20%
Property, Plant and Equipment, Net 514 K USD -62.2%
Assets 1.93 M USD -42.1%
Employee-related Liabilities, Current 667 K USD +0.03%
Liabilities, Current 3.62 M USD +10.3%
Operating Lease, Liability, Noncurrent 28.6 K USD -79.6%
Liabilities 3.63 M USD +4.56%
Retained Earnings (Accumulated Deficit) -59.9 M USD -9.39%
Stockholders' Equity Attributable to Parent -1.7 M USD -1123%
Liabilities and Equity 1.93 M USD -42.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -575 K USD +55.2%
Net Cash Provided by (Used in) Financing Activities -9 K USD +99.1%
Net Cash Provided by (Used in) Investing Activities -16 K USD +89.7%
Common Stock, Shares Authorized 2.5 B shares 0%
Common Stock, Shares, Issued 6.33 M shares -99.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 746 K USD -34%
Interest Paid, Excluding Capitalized Interest, Operating Activities 22 K USD +94.6%
Deferred Tax Assets, Valuation Allowance 5.56 M USD +42.6%
Deferred Tax Assets, Gross 5.87 M USD +39.7%
Operating Lease, Liability 82.4 K USD -67.6%
Depreciation 86.4 K USD -19.5%
Payments to Acquire Property, Plant, and Equipment 16 K USD -89.7%
Lessee, Operating Lease, Liability, to be Paid 266 K USD -0.51%
Property, Plant and Equipment, Gross 770 K USD -63.3%
Operating Lease, Liability, Current 49.8 K USD -58%
Lessee, Operating Lease, Liability, to be Paid, Year Two 28.9 K USD -74.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 238 K USD +89.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.59 K USD
Preferred Stock, Shares Authorized 10 M shares 0%
Operating Lease, Payments 5.48 K USD 0%
Additional Paid in Capital 58.2 M USD +9.54%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 19 K USD -87.8%
Share-based Payment Arrangement, Expense 23 K USD +1800%
Interest Expense 308 K USD -18.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%